Thank you for your interest in stem cell transplantation for Multiple Sclerosis. Our center is offering Autologous Hematopoietic Cell Transplantation (AHCT) as a treatment for select patients with relapsing/remitting MS (RMS). This treatment is available to patients who demonstrate evidence of disease activity despite treatment with best available MS medications, known as disease modifying therapies (DMTs). Patients who have evidence of disease activity on MRI or worsening disability will be considered.

Our team of researchers has previous experience with stem cell transplantation for MS. Given our own experience as well as the international experience, patients must meet the following selection criteria:

  • Must have relapsing remitting MS (not primary progressive (PPMS) or secondary progressive (SPMS) disease. Note: transplant studies for these will be available in the future
  • Must have two or more definite relapses in the past 24 months while receiving standard treatment for MS (see list below). Relapses include demonstrated neurological worsening (e.g. worsening gait or new findings on exam) or new contrast-enhancing lesions on MRI.
  • Must have had definite worsening disability by neurological exam while receiving standard treatment for MS (see list below) over the past 24 months. Meeting specific criteria (e.g. more difficulties with gait) in association with at least one of the relapses or stepwise worsening with relapses.
  • One or more relapse or loss of neurological function and at high-risk for future disability based on neurologist assessment.
  • Rapid loss of neurological function on treatment as assessed by neurologist.

Offering AHCT as a treatment plan for MS was previously available only as part of a research trial. This has changed based on evidence reviewed in a recent publication of MS treatment throughout U.S. and Canada. The authors found that immuno-chemotherapy followed by stem cell transplant is now considered an effective treatment for relapsing/remitting MS that are not responding to disease modifying therapies (DMTs).

Standard MS treatments (Must fail two or more to be eligible):

  • Interferon beta-1a (Avonex, Rebif)
  • Interferon beta-1b (Betaseron)
  • Glatiramer acetate (Copaxone)
  • Mitoxantrone (Novantrone)
  • Natalizumab (Tysabri)
  • Gilenya (Fingolimod)
  • Mavenclad (cladribine)
  • Mayzent (siponimod)
  • Mitoxantrone (Novantrone)
  • Ocrelizumab (OCREVUS)
  • Alemtuzumab
  • Other immunosuppressive agents

If you think you meet the criteria above, please contact our new patient coordinators at (720) 754-4835.